Rashes daclizumab

Skin One participant among six studied in a trial of high-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis developed a rash possibly induced by daclizumab [216 =]. 

Immunologic Two patients developed systemic immune responses 1-2 months after withdrawal of interferon beta, characterized by mouth ulcers, a photosensitivity rash, and transient formation of autoantibodies that required glucocorticoid therapy for resolution in an open baseline versus treatment phase II clinical trial of daclizumab in patients with multiple sclerosis and an inadequate response to interferon beta [211 ]. In rare cases severe hypersensitivity reactions after daclizumab have been reported. 

---